ZURICH, Aug 20 (Reuters) – Novartis has signed a
licensing deal to hand over its experimental tuberculosis (TB)
drugs to the Global Alliance for TB Drug Development, joining a
growing Big Pharma retreat from antibiotics.
The TB Alliance deal reflects renewed scrutiny of the
Novartis portfolio under new chairman Joerg Reinhardt, who is
focusing the Swiss company’s research on core areas such as
cancer, respiratory drugs, heart failure and dermatology.
ZURICH, Aug 7 (Reuters) – Adecco, the world’s
largest staffing company by sales, expects a modest economic
recovery to keep demand for temporary workers stable in Europe
as it reported a slight slowdown in underlying revenue growth in
the second quarter.
Employment agencies like Adecco and Dutch rival Randstad
are seen as barometers for economic health since
companies tend to hire temporary workers at the start of a
recovery when they are reluctant to commit to full-time hiring.
BASEL (Reuters) – Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.
Unlike other pharmaceutical companies that have been ravaged by patent losses, Roche has yet to face a challenge to its older biotech drugs by makers of copycat treatments and has launched a string of new, expensive cancer medicines.
ZURICH, July 23 (Reuters) – Charges linked to costly delays
to offshore wind and solar power projects pushed ABB’s
second-quarter earnings below forecasts, sending its shares down
2 percent on Wednesday.
Like many of its rivals, the Swiss company is suffering from
a lack of large orders for its power equipment and is working
its way through a backlog of less profitable contracts.
ZURICH, July 22 (Reuters) – Actelion Chief
Executive Jean-Paul Clozel said he was determined to keep the
Swiss biotech company independent, batting away speculation it
could become the next takeover target for U.S. firms seeking
lower taxes by relocating abroad.
Europe’s biggest biotech company has been rumoured as a
potential tax inversion target and its strong pipeline of drugs
to treat pulmonary arterial hypertension (PAH) could also
ZURICH/PARIS July 21 (Reuters) – Cement makers Holcim
and Lafarge have received more than 100
expressions of interest in assets they must sell ahead of their
planned merger, the Swiss company’s chief executive said on
The two companies proposed a multi-billion euro series of
asset sales two weeks ago in their efforts to get regulatory
approval for the planned merger, unveiled in April, which would
create a combined group with $44 billion in annual sales.
ZURICH, July 17 (Reuters) – Swiss drugmaker Novartis
posted a quarterly rise in sales that missed
expectations and said it would focus on eking out gradual cost
savings to boost margins as it prepares a radical business
Despite the sales miss, the Basel-based company confirmed
its full-year guidance for a rise in sales and profit, expecting
revenue from new products to offset generic competition to its
blood pressure pill Diovan.
ZURICH (Reuters) – Roche said its experimental Alzheimer’s drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients’ decline.
The Swiss drugmaker’s treatment known as crenezumab was tested in patients with mild-to-moderate forms of Alzheimer’s, a fatal, brain-wasting disease that gradually robs patients of their ability to think and care for themselves.
ZURICH (Reuters) – Swiss drugmaker Novartis has struck an agreement with Google to develop “smart” contact lenses that would help diabetics track their blood glucose levels or restore the eye’s ability to focus.
The device for diabetics would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis said. The technology is potentially life-changing for many diabetics, who prick their fingers as many as 10 times daily to check their body’s production of the sugar.
ZURICH (Reuters) – More than 200 budding Swiss songwriters have entered a public competition to come up with a new, more rousing national anthem, according to organizers who want to ditch a traditional work many view as far too solemn.
The contest, organized by the Swiss Society for Public Good, aims to replace “The Swiss Psalm” composed by Alberich Zwyssig, a Swiss monk, in 1841, which critics say is too hymn-like and at odds with modern-day Switzerland.